Bicyclic cyclohexylamines and their use as nmda receptor antagonists
申请人:——
公开号:US20030236252A1
公开(公告)日:2003-12-25
Described are bicycle-substituted cyclohexylamines of Formula (I) and their pharmaceutically acceptable salts thereof. The compounds are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinson's specification. disease. The substituents are defined in the specification.
1
Cyclohexylamine derivatives as subtype selective nmda receptor antagonists
申请人:——
公开号:US20030225164A1
公开(公告)日:2003-12-04
Described are cyclohexylamine derivatives of Formula (I), Formula (II) or Formula (III) and their pharmaceutically acceptable salts thereof. The compounds are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinson's disease. The substituents are described in the specification.
1
2-amino-1,2,3,4-tetrahydronaphthalene derivatives with cardiovascular
申请人:Chiesi Farmaceutici S.p.A.
公开号:US05096929A1
公开(公告)日:1992-03-17
5,6-Dimethoxy-2-[2-(4-hydroxyphenyl)-2-hydroxy-2-methylethyl]amino- 1,2,3,4-tetrahydronaphthalene has inotropic and vasodilating activities and therefore can be used in the treatment of cardiocirculatory failure. The compound can be in the form of a single stereoisomer or as a mixture of two or more stereoisomers.